# Clinical Trials Data KIT - Document 20

# Molecular Mechanisms and Diagnosis of Mastocytosis

## Clinical Trial: https://clinicaltrials.gov/study/NCT00336076

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Confirmed or suspected diagnosis of mastocytosis.\n\* Ability to give informed consent (by the patient or legal guardian if minor)\n\nExclusion Criteria:\n\n\* Inability or not willing to provide informed consent.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with confirmed or suspected mast cell disease",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The information provided doesn't say whether a KIT gene mutation is required for the trial. It \*only\* requires a confirmed or suspected diagnosis of mastocytosis. While KIT mutations are common in mastocytosis, they are not present in all cases. Therefore, a patient \*could\* be eligible with or without a KIT mutation, as long as they meet the other inclusion criteria (diagnosis) and don't meet the exclusion criteria (unable/unwilling to consent). More information would be needed to determine definitive eligibility.